Anti-inflammatory therapy with tumour necrosis factor alpha inhibitors improves high-density lipoprotein cholesterol antioxidative capacity in rheumatoid arthritis patients

What Was Tested

The paper reports a study of Copper (Supplement) in the context of high cholesterol and statins and rheumatoid arthritis, published as a clinical trial.

High-density lipoprotein (HDL) antiatherogenic functions seem to be diminished during inflammatory conditions such as rheumatoid arthritis (RA).

The aim of this study was to investigate the effects of tumour necrosis factor (TNF) inhibition on the antioxidative capacity of HDL in RA.

Who Took Part

The abstract describes 45 patients taking part.

By PubMed's age tags, the people studied were middle-aged adults and older adults, both men and women.

Plasma lipids and paraoxonase (PON-1) activity were investigated in 45 RA patients, before and during 6 months of anti-TNF therapy.

How the Study Was Run

The timeline in the abstract includes 6 months.

In addition, HDL was isolated and tested for its ability to inhibit copper-induced oxidation of low-density lipoprotein in vitro.

What Was Measured

The subject headings attached to it are Antibodies, Monoclonal, Antioxidants, Antirheumatic Agents, Arthritis, Rheumatoid, Aryldialkylphosphatase, Biomarkers and Blood Sedimentation.

What This Means in Plain Language

This is a clinical trial of Copper (Supplement) in 45 patients in people with high cholesterol and statins over 6 months.

Its findings take up roughly 7 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2009 (Annals of the rheumatic diseases), a journal based in United States.

More context: the Copper (Supplement) compound page, High cholesterol and statins research, Rheumatoid arthritis research.